Table 5.
Base-case cost-effectiveness results per patient
| Comparison | Total cost (£) | Total QALY | Incremental cost (£) | Incremental QALY | NMB (£)a |
|---|---|---|---|---|---|
| Aflibercept 2q8 | 25,859 | 8.54 | |||
| Ranibizumab 0.5 mg PRN | 20,019 | 8.59 | −5,841 | 0.05 | 6,768 |
| Ranibizumab 0.5 mg T&E | 22,930 | 8.59 | −2,930 | 0.05 | 3,934 |
Notes:
a
Assumes willingness-to-pay threshold of £20,000/QALY.
Abbreviations: QALY, quality-adjusted life-year; NMB, net monetary benefit; 2q8, 2 mg every 8 weeks after five initial monthly doses; PRN, pro re nata; T&E, treat and extend.